ERAS-5 / Erasca, LifeArc - LARVOL DELTA

Analysis of protocol adherence and outcomes of an enhanced recovery program in colorectal surgery after 5 years of implementation. (PubMed, J Healthc Qual Res) - "After five years of implementing an ERAS protocol for CRC in our hospital, we have managed to maintain a high adherence rate to ERAS strategies. There has been a significant reduction in HAIs and surgical site infections."

Journal • Infectious Disease

Perioperative Venous Thromboembolism Chemoprophylaxis Does Not Increase Risk of Complications in Free Flap Breast Reconstruction. (PubMed, J Surg Oncol) - "A standardized perioperative anticoagulation protocol for abdominal-based breast reconstruction maintained low VTE rates without increasing hematoma, flap failure, or reoperation."

Journal • Cardiovascular • Hematological Disorders • Respiratory Diseases • Venous Thromboembolism

Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway (GlobeNewswire) - "As such, we are deprioritizing our ERAS-601 clinical trial (FLAGSHP-1) and our preclinical ERAS-5 ULK inhibitor and ERAS-10 protein degrader programs."

Pipeline update • Trial status • Oncology • Solid Tumor